| Project/Area Number |
26860533
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Osaka Medical College |
|---|
Principal Investigator |
Asai Akira 大阪医科大学, 医学部, 講師 (30622146)
|
|---|
| Research Collaborator |
Suzuki Fujio University of Texas Medical Branch, Internal Medicine/Infectious Diseases, Professor
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2015: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 単球 / 肝細胞癌 / CCL1 / マクロファージ |
|---|
| Outline of Final Research Achievements |
Despite major advances in curative and palliative approaches, hepatocellular carcinoma (HCC) is still the third leading cause of cancer-related death worldwide. M1 monocytes play a key role in host antitumor defenses in HCC. The majority of monocytes from early HCC stage patients switched to the M1 phenotype (IL-12+IL-10－iNOS+cells), whereas the majority of monocytes from advanced HCC stage patients did not switch to the M1 phenotype and continued to express M2b phenotypic properties (IL-12－IL-10+CCL1+iNOS－cells). Monocytes from advanced HCC stage patients showed M1 polarization after treatment with CCL1 antisense oligodeoxynucleotide (ODN). Therefore, our study indicates that anti-HCC defenses of advanced HCC stage patients may be improved after CCL1 antisense ODN treatment.
|
